HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable ongoing efficacy results from follow-up visits for Patient 4 and Patient 6 in its ...
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports interim results near the completion of Part 1 of its Deltacel-01 Phase 1 clinical trial. This trial ...
HOUSTON--(BUSINESS WIRE)-- Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that the University of Arizona Cancer Center (UACC) has been activated as the fifth clinical ...
HOUSTON--(BUSINESS WIRE)-- Kiromic BioPharma, Inc. (KRBP) (“Kiromic” or the “Company”) reports good safety and favorable ongoing efficacy results from the 10-month follow-up visit of the first patient ...
A new type of immunotherapy, developed by UCL researchers, has shown promising preclinical results against a bone cancer called osteosarcoma, as part of a study in mice. Osteosarcoma is the most ...
A new type of immunotherapy, developed by UCL researchers, has shown promising preclinical results against a bone cancer called osteosarcoma, as part of a study in mice. Osteosarcoma is the most ...
A new type of immunotherapy has shown promising preclinical results against a bone cancer called osteosarcoma, as part of a study in mice. A new type of immunotherapy, developed by UCL researchers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback